Screening for cognition in amyotrophic lateral sclerosis: test characteristics of a new screen.


Journal

Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161

Informations de publication

Date de publication:
Jul 2021
Historique:
received: 23 11 2020
accepted: 22 01 2021
revised: 18 01 2021
pubmed: 7 2 2021
medline: 24 6 2021
entrez: 6 2 2021
Statut: ppublish

Résumé

Cognitive and behavioural impairment in amyotrophic lateral sclerosis (ALS) negatively influences the quality of life and survival, and, therefore, screening for these impairments is recommended. We developed a cognitive screening tool, the amyotrophic lateral sclerosis-frontotemporal dementia-cognitive screen (ALS-FTD-Cog) and aimed to validate it in patients with ALS. During the current study, the Edinburgh Cognitive and Behavioural ALS Screen (ECAS) was published and we, therefore, decided to compare these two cognitive screening methods. The ALS-FTD-Cog was administered to 72 patients with ALS, 21 patients with behavioural variant FTD (bvFTD) and 34 healthy controls. Twenty-nine patients with ALS underwent the ECAS. ROC curve analyses were performed and sensitivity and specificity of the ALS-FTD-Cog and ECAS were calculated, with a neuropsychological examination (NPE) as the gold standard. Cognitive impairment was present in 28% of patients with ALS. ROC curve analyses of the ALS-FTD-Cog and ECAS showed an area under the curve (AUC) of 0.72 (95% CI 0.58-0.86) and 0.95 (95% CI 0.86-1.03), respectively. Compared to a full NPE, sensitivity and specificity of the ALS-FTD-Cog were 65.0% and 63.5% and of the ECAS 83.3% and 91.3%, respectively. The sensitivity and specificity of the ALS-FTD-Cog in patients with bvFTD were 94.4% and 100%, respectively. Test characteristics of the ALS-FTD-Cog were moderate, suggesting restricted practical value, as compared to a comprehensive NPE. The ECAS had an excellent AUC and high sensitivity and specificity, indicating that it is a valid screening instrument for cognitive impairment in ALS.

Identifiants

pubmed: 33547953
doi: 10.1007/s00415-021-10423-x
pii: 10.1007/s00415-021-10423-x
pmc: PMC8217007
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2533-2540

Subventions

Organisme : Stichting ALS Nederland
ID : 2013-19

Références

Caga J, Hsieh S, Lillo P, Dudley K, Mioshi E (2019) The impact of cognitive and behavioral symptoms on ALS patients and their caregivers. Front Neurol 10:192. https://doi.org/10.3389/fneur.2019.00192
doi: 10.3389/fneur.2019.00192 pubmed: 30915018 pmcid: 6421295
Chio A, Vignola A, Mastro E, Giudici AD, Iazzolino B, Calvo A, Moglia C, Montuschi A (2010) Neurobehavioral symptoms in ALS are negatively related to caregivers’ burden and quality of life. Eur J Neurol 17(10):1298–1303. https://doi.org/10.1111/j.1468-1331.2010.03016.x
doi: 10.1111/j.1468-1331.2010.03016.x pubmed: 20402747
Govaarts R, Beeldman E, Kampelmacher MJ, van Tol MJ, van den Berg LH, van der Kooi AJ, Wijkstra PJ, Zijnen-Suyker M, Cobben NA, Schmand BA, de Haan RJ, de Visser M, Raaphorst J (2016) The frontotemporal syndrome of ALS is associated with poor survival. J Neurol 263(12):2476–2483. https://doi.org/10.1007/s00415-016-8290-1
doi: 10.1007/s00415-016-8290-1 pubmed: 27671483 pmcid: 5110703
Xu Z, Alruwaili ARS, Henderson RD, McCombe PA (2017) Screening for cognitive and behavioural impairment in amyotrophic lateral sclerosis: frequency of abnormality and effect on survival. J Neurol Sci 376:16–23. https://doi.org/10.1016/j.jns.2017.02.061
doi: 10.1016/j.jns.2017.02.061 pubmed: 28431606
Strong MJ, Abrahams S, Goldstein LH, Woolley S, McLaughlin P, Snowden J, Mioshi E, Roberts-South A, Benatar M, HortobaGyi T, Rosenfeld J, Silani V, Ince PG, Turner MR (2017) Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): revised diagnostic criteria. Amyotroph Lateral Scler Frontotemporal Degener 18(3–4):153–174. https://doi.org/10.1080/21678421.2016.1267768
doi: 10.1080/21678421.2016.1267768 pubmed: 28054827 pmcid: 7409990
Goldstein LH, Abrahams S (2013) Changes in cognition and behaviour in amyotrophic lateral sclerosis: nature of impairment and implications for assessment. Lancet Neurol 12(4):368–380. https://doi.org/10.1016/S1474-4422(13)70026-7
doi: 10.1016/S1474-4422(13)70026-7 pubmed: 23518330
Woolley SC, York MK, Moore DH, Strutt AM, Murphy J, Schulz PE, Katz JS (2010) Detecting frontotemporal dysfunction in ALS: utility of the ALS Cognitive Behavioral Screen (ALS-CBS). AmyotrophLateral Scler 11(3):303–311. https://doi.org/10.3109/17482961003727954
doi: 10.3109/17482961003727954
Flaherty-Craig C, Brothers A, Dearman B, Eslinger P, Simmons Z (2009) Penn State screen exam for the detection of frontal and temporal dysfunction syndromes: application to ALS. Amyotroph Lateral Scler 10(2):107–112. https://doi.org/10.1080/17482960802378980
doi: 10.1080/17482960802378980 pubmed: 18792849
Abrahams S, Newton J, Niven E, Foley J, Bak TH (2013) Screening for cognition and behaviour changes in ALS. Amyotroph Lateral Scler Frontotemporal Degener. https://doi.org/10.3109/21678421.2013.805784
doi: 10.3109/21678421.2013.805784 pubmed: 23781974
Hu WT, Shelnutt M, Wilson A, Yarab N, Kelly C, Grossman M, Libon DJ, Khan J, Lah JJ, Levey AI, Glass J (2013) Behavior matters–cognitive predictors of survival in amyotrophic lateral sclerosis. PLoS ONE 8(2):e57584. https://doi.org/10.1371/journal.pone.0057584
doi: 10.1371/journal.pone.0057584 pubmed: 23460879 pmcid: 3583832
Murphy J, Ahmed F, Lomen-Hoerth C (2015) The UCSF screening exam effectively screens cognitive and behavioral impairment in patients with ALS. Amyotroph Lateral Scler Frontotemporal Degener 16(1–2):24–30. https://doi.org/10.3109/21678421.2014.960873
doi: 10.3109/21678421.2014.960873 pubmed: 25301548
Gosselt IK, Nijboer TCW, Van Es MA (2020) An overview of screening instruments for cognition and behavior in patients with ALS: selecting the appropriate tool for clinical practice. Amyotroph Lateral Scler Frontotemporal Degener 2020:1–13. https://doi.org/10.1080/21678421.2020.1732424
doi: 10.1080/21678421.2020.1732424
Beeldman E, Raaphorst J, Klein Twennaar M, de Visser M, Schmand BA, de Haan RJ (2016) The cognitive profile of ALS: a systematic review and meta-analysis update. J Neurol Neurosurg Psychiatry 6:611–619. https://doi.org/10.1136/jnnp-2015-310734
doi: 10.1136/jnnp-2015-310734
Taylor LJ, Brown RG, Tsermentseli S, Al-Chalabi A, Shaw CE, Ellis CM, Leigh PN, Goldstein LH (2013) Is language impairment more common than executive dysfunction in amyotrophic lateral sclerosis? J Neurol Neurosurg Psychiatry 84(5):494–498. https://doi.org/10.1136/jnnp-2012-303526
doi: 10.1136/jnnp-2012-303526 pubmed: 23033353
Abrahams S, Leigh PN, Harvey A, Vythelingum GN, Grise D, Goldstein LH (2000) Verbal fluency and executive dysfunction in amyotrophic lateral sclerosis (ALS). Neuropsychologia 38(6):734–747
doi: 10.1016/S0028-3932(99)00146-3
Raaphorst J, van Tol MJ, de Visser M, van der Kooi AJ, Majoie CB, van den Berg LH, Schmand B, Veltman DJ (2015) Prose memory impairment in amyotrophic lateral sclerosis patients is related to hippocampus volume. Eur J Neurol 22(3):547–554. https://doi.org/10.1111/ene.12615
doi: 10.1111/ene.12615 pubmed: 25557180
Brooks BR, Miller RG, Swash M, Munsat TL (2000) El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1(5):293–299
doi: 10.1080/146608200300079536
Beeldman E, Govaarts R, de Visser M, Klein Twennaar M, van der Kooi AJ, van den Berg LH, Veldink JH, Pijnenburg YAL, de Haan RJ, Schmand BA, Raaphorst J (2020) Progression of cognitive and behavioural impairment in early amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. https://doi.org/10.1136/jnnp-2020-322992
doi: 10.1136/jnnp-2020-322992 pubmed: 32404381
Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, van Swieten JC, Seelaar H, Dopper EG, Onyike CU, Hillis AE, Josephs KA, Boeve BF, Kertesz A, Seeley WW, Rankin KP, Johnson JK, Gorno-Tempini ML, Rosen H, Prioleau-Latham CE, Lee A, Kipps CM, Lillo P, Piguet O, Rohrer JD, Rossor MN, Warren JD, Fox NC, Galasko D, Salmon DP, Black SE, Mesulam M, Weintraub S, Dickerson BC, Diehl-Schmid J, Pasquier F, Deramecourt V, Lebert F, Pijnenburg Y, Chow TW, Manes F, Grafman J, Cappa SF, Freedman M, Grossman M, Miller BL (2011) Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 134(Pt 9):2456–2477. https://doi.org/10.1093/brain/awr179
doi: 10.1093/brain/awr179 pubmed: 21810890 pmcid: 3170532
Girardi A, Macpherson SE, Abrahams S (2011) Deficits in emotional and social cognition in amyotrophic lateral sclerosis. Neuropsychology 25(1):53–65. https://doi.org/10.1037/a0020357
doi: 10.1037/a0020357 pubmed: 20919762
Meier SL, Charleston AJ, Tippett LJ (2010) Cognitive and behavioural deficits associated with the orbitomedial prefrontal cortex in amyotrophic lateral sclerosis. Brain 133(11):3444–3457. https://doi.org/10.1093/brain/awq254
doi: 10.1093/brain/awq254 pubmed: 20889583
Bora E (2017) Meta-analysis of social cognition in amyotrophic lateral sclerosis. Cortex 88:1–7. https://doi.org/10.1016/j.cortex.2016.11.012
doi: 10.1016/j.cortex.2016.11.012 pubmed: 28002755
Raaphorst J, Beeldman E, Schmand B, Berkhout J, Linssen WH, van den Berg LH, Pijnenburg YA, Grupstra HF, Weikamp JG, Schelhaas HJ, Papma JM, van Swieten JC, de Visser M, de Haan RJ (2012) The ALS-FTD-Q: a new screening tool for behavioral disturbances in ALS. Neurology 79(13):1377–1383
doi: 10.1212/WNL.0b013e31826c1aa1
Mioshi E, Hsieh S, Caga J, Ramsey E, Chen K, Lillo P, Simon N, Vucic S, Hornberger M, Hodges JR, Kiernan MC (2014) A novel tool to detect behavioural symptoms in ALS. Amyotroph Lateral Scler Frontotemporal Degener 15(3–4):298–304. https://doi.org/10.3109/21678421.2014.896927
doi: 10.3109/21678421.2014.896927 pubmed: 24863641
Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, Nakanishi A (1999) The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci 169(1–2):13–21
doi: 10.1016/S0022-510X(99)00210-5
Spinhoven P, Ormel J, Sloekers PP, Kempen GI, Speckens AE, Van Hemert AM (1997) A validation study of the Hospital Anxiety and Depression Scale (HADS) in different groups of Dutch subjects. Psychol Med 27(2):363–370
doi: 10.1017/S0033291796004382
Crockford C, Newton J, Lonergan K, Chiwera T, Booth T, Chandran S, Colville S, Heverin M, Mays I, Pal S, Pender N, Pinto-Grau M, Radakovic R, Shaw CE, Stephenson L, Swingler R, Vajda A, Al-Chalabi A, Hardiman O, Abrahams S (2018) ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS. Neurology. https://doi.org/10.1212/WNL.0000000000006317
doi: 10.1212/WNL.0000000000006317 pubmed: 30209236 pmcid: 6177274
Phukan J, Elamin M, Bede P, Jordan N, Gallagher L, Byrne S, Lynch C, Pender N, Hardiman O (2012) The syndrome of cognitive impairment in amyotrophic lateral sclerosis: a population-based study. J Neurol Neurosurg Psychiatry 83(1):102–108. https://doi.org/10.1136/jnnp-2011-300188
doi: 10.1136/jnnp-2011-300188 pubmed: 21836033
Gossink F, Schouws S, Krudop W, Scheltens P, Stek M, Pijnenburg Y, Dols A (2018) Social cognition differentiates behavioral variant frontotemporal dementia from other neurodegenerative diseases and psychiatric disorders. Am J Geriatr Psychiatry 26(5):569–579. https://doi.org/10.1016/j.jagp.2017.12.008
doi: 10.1016/j.jagp.2017.12.008 pubmed: 29501411
Bora E, Velakoulis D, Walterfang M (2016) Meta-analysis of facial emotion recognition in behavioral variant frontotemporal dementia: comparison with Alzheimer disease and healthy controls. J Geriatr Psychiatry Neurol 29(4):205–211. https://doi.org/10.1177/0891988716640375
doi: 10.1177/0891988716640375 pubmed: 27056068
Abdulla S, Machts J, Kaufmann J, Patrick K, Kollewe K, Dengler R, Heinze HJ, Petri S, Vielhaber S, Nestor PJ (2014) Hippocampal degeneration in patients with amyotrophic lateral sclerosis. Neurobiol Aging 35(11):2639–2645. https://doi.org/10.1016/j.neurobiolaging.2014.05.035
doi: 10.1016/j.neurobiolaging.2014.05.035 pubmed: 25004891
Bede P, Elamin M, Byrne S, McLaughlin RL, Kenna K, Vajda A, Pender N, Bradley DG, Hardiman O (2013) Basal ganglia involvement in amyotrophic lateral sclerosis. Neurology 81(24):2107–2115. https://doi.org/10.1212/01.wnl.0000437313.80913.2c
doi: 10.1212/01.wnl.0000437313.80913.2c pubmed: 24212388
Machts J, Loewe K, Kaufmann J, Jakubiczka S, Abdulla S, Petri S, Dengler R, Heinze HJ, Vielhaber S, Schoenfeld MA, Bede P (2015) Basal ganglia pathology in ALS is associated with neuropsychological deficits. Neurology 85(15):1301–1309. https://doi.org/10.1212/WNL.0000000000002017
doi: 10.1212/WNL.0000000000002017 pubmed: 26385880
Wightman G, Anderson VE, Martin J, Swash M, Anderton BH, Neary D, Mann D, Luthert P, Leigh PN (1992) Hippocampal and neocortical ubiquitin-immunoreactive inclusions in amyotrophic lateral sclerosis with dementia. Neurosci Lett 139(2):269–274. https://doi.org/10.1016/0304-3940(92)90569-s
doi: 10.1016/0304-3940(92)90569-s pubmed: 1376881
Lule D, Burkhardt C, Abdulla S, Bohm S, Kollewe K, Uttner I, Abrahams S, Bak TH, Petri S, Weber M, Ludolph AC (2015) The Edinburgh cognitive and behavioural amyotrophic lateral sclerosis screen: a cross-sectional comparison of established screening tools in a German-Swiss population. Amyotroph Lateral Scler Frontotemporal Degener 16(1–2):16–23. https://doi.org/10.3109/21678421.2014.959451
doi: 10.3109/21678421.2014.959451 pubmed: 25292386
Mora JS, Salas T, Fernandez MC, Rodriguez-Castillo V, Marin S, Chaverri D, Rodriguez-Santos F (2018) Spanish adaptation of the Edinburgh cognitive and behavioral amyotrophic lateral sclerosis screen (ECAS). Amyotroph Lateral Scler Frontotemporal Degener 19(1–2):74–79. https://doi.org/10.1080/21678421.2017.1406952
doi: 10.1080/21678421.2017.1406952 pubmed: 29212378
Niven E, Newton J, Foley J, Colville S, Swingler R, Chandran S, Bak TH, Abrahams S (2015) Validation of the Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis Screen (ECAS): a cognitive tool for motor disorders. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 16(3–4):172–179. https://doi.org/10.3109/21678421.2015.1030430
doi: 10.3109/21678421.2015.1030430 pubmed: 25967542

Auteurs

Emma Beeldman (E)

Department of Neurology, Amsterdam UMC, Academic Medical Centre, University of Amsterdam, P.O. Box 22700, Amsterdam, The Netherlands. e.beeldman@amsterdamumc.nl.

Rosanne Govaarts (R)

Department of Neurology, Amsterdam UMC, Academic Medical Centre, University of Amsterdam, P.O. Box 22700, Amsterdam, The Netherlands.

Marianne de Visser (M)

Department of Neurology, Amsterdam UMC, Academic Medical Centre, University of Amsterdam, P.O. Box 22700, Amsterdam, The Netherlands.

Michael A van Es (MA)

Department of Neurology, University Medical Centre Utrecht Brain Centre, Utrecht, The Netherlands.

Yolande A L Pijnenburg (YAL)

Alzheimer Centre, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands.

Ben A Schmand (BA)

Department of Medical Psychology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.

Joost Raaphorst (J)

Department of Neurology, Amsterdam UMC, Academic Medical Centre, University of Amsterdam, P.O. Box 22700, Amsterdam, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH